Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657033 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction
A Phase 3 study of Erectile Dysfunction, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 229
- Enrollment target
- 20
- Study locations
NCT00657033: Completed Phase 3 study of Erectile Dysfunction, sponsored by Bayer.
NCT00657033 is a Phase 3 study of Erectile Dysfunction that has completed, run by Bayer. The registered enrollment target is 229 participants, roughly in line with the 225-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00657033, a Phase 3 study of Erectile Dysfunction, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 229 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levitra (Vardenafil, BAY38-9456)
Study Locations (20)
California
- - Beverly Hills
- - Irvine
- - Newport Beach
- - San Bernardino
- - San Diego
- - San Diego
North Carolina
- - Charlotte
- - Statesville
- - Wilmington
Maryland
- - Greenbelt
- - Lutherville
New Jersey
- - Lawrenceville
- - New Brunswick
Arizona
- - Phoenix
Connecticut
- - Trumbull
Florida
- - Jacksonville
Georgia
- - Riverdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-08 |
| Phase | Phase 3 |
What the finished NCT00657033 record still lists
NCT00657033 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 225-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target.
The record links to 1 condition, with Erectile Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00657033 names 20 study sites across 11 states, led by California, North Carolina, Maryland.
Frequently Asked Questions
What is clinical trial NCT00657033 about?
NCT00657033 is a clinical study titled "Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction". Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.
What is the current status of trial NCT00657033?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 229 participants. The study started on 2003-10. Estimated completion is 2004-08.
What conditions does trial NCT00657033 study?
This clinical trial studies the following conditions: Erectile Dysfunction.
What interventions are being tested in trial NCT00657033?
The interventions under investigation include: Placebo (DRUG), Levitra (Vardenafil, BAY38-9456) (DRUG).
Who is sponsoring clinical trial NCT00657033?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00657033 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erectile Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00657033's enrollment target sits among peer trials
229 8th of 33 higher than 26 of 33 other Erectile Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Erectile Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Actual Use Trial of Tadalafil 5 mg
RECRUITING · Phase 3
-
Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
COMPLETED · Phase 3
-
Treatment of Erectile Dysfunction II
COMPLETED · Phase 3
-
Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia